Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Nonresectable Adrenocortical Cancer
NCT00469469Phase 2Withdrawn
- Sponsor
- Dartmouth Health
- Start
- May 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in adrenocortical carcinoma (ACC), sponsored by Dartmouth Health. Planned start May 2007; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT00469469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00469469.